Literature DB >> 31414929

Preeclamptic Women Are at Significantly Higher Risk of Future Cardiovascular Outcomes Over a 15-Year Period.

Mary Downes Gastrich1,2, Stavros Zinonos1, Gloria Bachmann2, Nora M Cosgrove1, Javier Cabrera1,3, Jerry Q Cheng1, John B Kostis1.   

Abstract

Background: Preeclampsia (PE) may lead to maternal and infant mortality and severe medical complications. Understanding future short- and long-term cardiovascular (CV) outcomes of PE is important to women's health. Materials and
Methods: A retrospective matched case-control study assessed the risks of CV outcomes over a 15-year period (1999-2013) in pregnant case women, with gravidity and parity of one, diagnosed with PE, compared to pregnant primiparous control women who were not diagnosed with PE. The New Jersey Electronic Birth Certificate (EBC) database and the Myocardial Infarction Data Acquisition System (MIDAS), a database of all hospital admissions in New Jersey with longitudinal follow-up, were used to conduct the analysis. Participants were 18 years and older with demographics consistent with New Jersey, a state with a range of racial and ethnic diversity. Main outcome measures postpregnancy and over this 15-year period were myocardial infarction (MI), stroke, CV death, and all-cause death.
Results: Women with PE (N = 6,360) were more likely to suffer MI, stroke, CV death, and all-cause death than controls (N = 325,347). After matching cases to controls for demographics and comorbidities, hazard ratios of PE cases for the outcomes of MI (p adjusted for comorbidities and demographics = 0.0196), CV death (adjusted p = 0.007), and all-cause death (adjusted p = 0.0026) were significantly higher than 1 compared to matched controls. Women with PE had 3.94 (95% CI: 1.25-12.4) times higher hazard for MI, 4.66 (95% CI: 1.52-14.26) times higher hazard of CV death, and 2.32 (95% CI: 1.34-4.02) times higher hazard for all-cause death than matched controls. Conclusions: This 15-year study indicates that women who have PE with their first pregnancy have a significantly higher risk of adverse CV outcomes compared to controls and suggest a heightened and continued CV monitoring after birth for this population of women.

Entities:  

Keywords:  cardiovascular outcomes; death; myocardial infarction; preeclampsia

Mesh:

Year:  2019        PMID: 31414929     DOI: 10.1089/jwh.2019.7671

Source DB:  PubMed          Journal:  J Womens Health (Larchmt)        ISSN: 1540-9996            Impact factor:   2.681


  9 in total

1.  Association between aspirin use during pregnancy and cardiovascular risk factors 2-7 years after delivery: The nuMoM2b Heart Health Study.

Authors:  Lauren H Theilen; Philip Greenland; Jasmina Varagic; Janet Catov; Anthony Shanks; Vanessa Thorsten; Corette B Parker; Rebecca McNeil; Brian Mercer; Matthew Hoffman; Ronald Wapner; David Haas; Hyagriv Simhan; William Grobman; Judith H Chung; Lisa D Levine; Shannon Barnes; Noel Bairey Merz; George Saade; Robert M Silver
Journal:  Pregnancy Hypertens       Date:  2022-02-04       Impact factor: 2.494

Review 2.  A Review of the Potential Interaction of Selenium and Iodine on Placental and Child Health.

Authors:  Nahal Habibi; Jessica A Grieger; Tina Bianco-Miotto
Journal:  Nutrients       Date:  2020-09-02       Impact factor: 5.717

3.  Previous preeclampsia and its association with the future development of cardiovascular diseases: a systematic review and meta-analysis.

Authors:  Eduardo Carvalho de Arruda Veiga; Paulo Ricardo Higassiaraguti Rocha; Leonardo L Caviola; Viviane Cunha Cardoso; Fabricio da Silva Costa; Maria da Conceição Pereira Saraiva; Marco Antonio Barbieri; Heloisa Bettiol; Ricardo Carvalho Cavalli
Journal:  Clinics (Sao Paulo)       Date:  2021-01-20       Impact factor: 2.365

Review 4.  Maternal Morbidity and Mortality: Are We Getting to the "Heart" of the Matter?

Authors:  Jasmina Varagic; Patrice Desvigne-Nickens; Joyonna Gamble-George; Lisa Hollier; Christine Maric-Bilkan; Megan Mitchell; Victoria L Pemberton; Nicole Redmond
Journal:  J Womens Health (Larchmt)       Date:  2020-12-01       Impact factor: 2.681

5.  Genetic markers for preeclampsia in Peruvian women.

Authors:  José Pacheco-Romero; Oscar Acosta; Doris Huerta; Santiago Cabrera; Marlene Vargas; Pedro Mascaro; Moisés Huamán; José Sandoval; Rudy López; Julio Mateus; Enrique Gil; Enrique Guevara; Nitza Butrica; Diana Catari; David Bellido; Gina Custodio; Andrea Naranjo
Journal:  Colomb Med (Cali)       Date:  2021-02-26

Review 6.  Use of Race, Ethnicity, and National Origin in Studies Assessing Cardiovascular Risk in Women With a History of Hypertensive Disorders of Pregnancy.

Authors:  Amy Johnston; Victrine Tseung; Sonia R Dancey; Sarah M Visintini; Thais Coutinho; Jodi D Edwards
Journal:  CJC Open       Date:  2021-08-20

7.  Trends in Prepregnancy Obesity and Association With Adverse Pregnancy Outcomes in the United States, 2013 to 2018.

Authors:  Michael C Wang; Priya M Freaney; Amanda M Perak; Philip Greenland; Donald M Lloyd-Jones; William A Grobman; Sadiya S Khan
Journal:  J Am Heart Assoc       Date:  2021-08-25       Impact factor: 5.501

8.  The Association Between Hypertensive Disorders in Pregnancy and the Risk of Developing Chronic Hypertension.

Authors:  Jiahao Xu; Ting Li; Yixiao Wang; Lu Xue; Zhijing Miao; Wei Long; Kaipeng Xie; Chen Hu; Hongjuan Ding
Journal:  Front Cardiovasc Med       Date:  2022-07-07

9.  Serum Cotinine and Adverse Cardiovascular Outcomes: A Cross-sectional Secondary Analysis of the nuMoM2b Heart Health Study.

Authors:  Lauren H Theilen; Rebecca B McNeil; Shannon Hunter; William A Grobman; Corette B Parker; Janet M Catov; Victoria L Pemberton; Deborah B Ehrenthal; David M Haas; Matthew K Hoffman; Judith H Chung; Farhana Mukhtar; Zorayr Arzumanyan; Brian Mercer; Samuel Parry; George R Saade; Hyagriv N Simhan; Ronald J Wapner; Robert M Silver
Journal:  Am J Perinatol       Date:  2021-08-06       Impact factor: 3.079

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.